Inlet Private Wealth LLC Acquires 48,280 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Inlet Private Wealth LLC raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 25.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,740 shares of the biopharmaceutical company’s stock after buying an additional 48,280 shares during the period. Royalty Pharma accounts for approximately 1.6% of Inlet Private Wealth LLC’s portfolio, making the stock its 17th biggest holding. Inlet Private Wealth LLC’s holdings in Royalty Pharma were worth $6,039,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in RPRX. Blue Trust Inc. lifted its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 376 shares during the last quarter. Aurora Investment Counsel increased its position in Royalty Pharma by 1.0% during the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock worth $1,427,000 after acquiring an additional 512 shares during the period. GAMMA Investing LLC increased its position in Royalty Pharma by 31.4% during the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 590 shares during the period. Values First Advisors Inc. raised its stake in Royalty Pharma by 7.6% during the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 738 shares during the last quarter. Finally, M&T Bank Corp boosted its holdings in Royalty Pharma by 4.3% in the 3rd quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 779 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Down 0.0 %

Shares of RPRX opened at $31.58 on Friday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market cap of $18.61 billion, a price-to-earnings ratio of 16.36 and a beta of 0.47. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $32.21. The company has a 50-day moving average price of $27.34 and a two-hundred day moving average price of $27.53.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Analyst Ratings Changes

RPRX has been the topic of several research reports. Citigroup dropped their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.